Recently,Metformin Hydrochloride Tablet (0.25g), a diabetes drug owned by SihuanPharmaceutical Holdings Group, has been approved by the State DrugAdministration and has passed the evaluation on quality and efficacy of genericdrug, and Sihuan has become the first domestic company to obtain an approvalupon additional application based on consistency evaluation in connection withsuch drug.
MetforminHydrochloride Tablet is a basic drug for treating diabetes, and is used inpatients with type II diabetes whose blood sugar cannot be satisfactorilycontrolled by diet alone, especially those obese people and those accompanyingwith hyperinsulinemia. As a first-line drug for treating type II diabetes,Metformin is often used in combination with other oral hypoglycemic drug.According to recent research results, in addition to the hypoglycemic effect,Metformin also has multiple clinical benefits, including protection ofcardio-cerebral vascular and improvement of non-alcoholic fatty liver disease.Because of its advantages in efficacy and accessibility, it has been listed asfirst-line drug for hypoglycemic treatment in the guidelines for theprevention and treatment of type II diabetes developed by professional academicorganizations at home and abroad.
Withthe continuous increase in the incidence of hyperglycaemia in China, there is astable market demand for Metformin preparations. According to Menet database,in 2017, Metformin achieved a sales of RMB 2.59 billion in (city-level publicand county-level public) hospitals across the country and ranked second amongdomestic oral hypoglycemic drugs (CADN) in terms of market size.
Havingpassed the consistency evaluation earlier than others, Sihuan Pharmaceuticalhas undoubtedly seized the policy and market opportunities. The product’ssuccessful passing the consistency evaluation is the authoritative recognitionof Sihuan's R&D capability, production and product quality and productefficacy, and also gives it an advantage in future market access, medical insurancepayment and other areas.